Actively Recruiting

Age: 18Years +
All Genders
NCT04746534

Cohort SURVI : Intestinal Ischemia and Vascular Diseases

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2021-02-09

20000

Participants Needed

1

Research Sites

1049 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The first Intestinal Vascular Emergency Unit (SURVI), with the institutional support of AP-HP, opened on 4 January 2016, within the Paris-Nord Val de Seine University Hospital Group. This intensive care is dedicated to the management of mesenteric ischemias (acute mesenteric ischemias, chronic mesenteric ischemias) and Intestinal Vascular Diseases Without Ischemia. The organisation of this type of dedicated centre, combining advances in resuscitation, interventional radiology and knowledge of intestinal vascular diseases, has led to a radical change in the prognosis for acute mesenteric ischaemia with a survival rate of over 80% and an intestinal resection rate of less than 40%. Acute mesenteric ischaemia (AMI) is characterised by the combination of digestive distress and vascular insufficiency: occlusive (thrombosis, embolism, arterial, venous) or non-occlusive (low flow or vasospasm). The vital prognosis is catastrophic in the absence of treatment (the mortality rate of an intestinal infarction is almost 100% without treatment), and the functional and anatomical after-effects are major for the survivors. Many intestinal vascular diseases have been identified as providing acute and chronic mesenteric ischaemia. The nosological framework of these diseases is broad, ranging from constitutional diseases of the vessels (collagenosis, arcuate ligament syndrome) to acquired diseases of a thrombophilic, cardiac, degenerative, autoimmune, iatrogenic, traumatic nature... The rarity of these diseases (with the exception of atherosclerotic disease, the incidence of which is increasing with the ageing of the population) makes their level of knowledge insufficient. The natural history of vascular diseases without ischaemia (rate of acute and chronic mesenteric ischaemia, mortality rate, resection rate...) is currently not described. The construction of a longitudinal observational cohort is necessary for the prevalence of ischaemic complications and predictive factors.

CONDITIONS

Official Title

Cohort SURVI : Intestinal Ischemia and Vascular Diseases

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age over 18 years
  • Acute mesenteric ischemia defined by sudden digestive distress due to arterial or venous vascular insufficiency without alternative diagnosis
  • Chronic mesenteric ischemia defined by digestive distress lasting more than 30 days related to arterial or venous vascular insufficiency
  • Gastrointestinal arterial or venous diseases without ischemia such as atheroma, embolism, thrombosis, dissection, mediolysis, aneurysm, dysplasia, sheathing, compression, or torsion
Not Eligible

You will not qualify if you...

  • Left ischemic colitis without damage to the celiac trunk or superior mesenteric artery
  • Dissection of the abdominal aorta without intestinal ischemia
  • Portal vein thrombosis without extension to the superior mesenteric vein
  • Traumatic rupture of digestive arteries
  • No abdominal CT scan performed or no contrast-enhanced abdominal CT scan
  • Patient refuses to participate in research
  • Patient under guardianship or curatorship
  • Vulnerable patients including pregnant or breastfeeding women, persons deprived of liberty, minors, or adults unable or unwilling to give consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Olivier CORCOS

Clichy, France, 92110

Actively Recruiting

Loading map...

Research Team

O

Olivier CORCOS

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here